Monocationic radiotracer kinetics and myocardial infarct size: a perfused rat heart study
- 77 Downloads
- 1 Citations
Abstract
Objective
To compare the myocardial kinetics of three 99mtechnetium-labeled monocationic tracers [methoxy-isobutylisonitrile (MIBI), tetrofosmin, and Q12] in a model of ischemia-reperfusion (IR) to determine their abilities to assess myocardial viability.
Methods
Isolated perfused rat hearts (n = 30) were studied in control and IR groups for each tracer. IR hearts were treated with 120 min global no-flow followed by 5 min reflow, then 60 min tracer uptake/clearance. Tracer kinetics were monitored using a scintillation detector.
Results
This model produced significant myocardial injury, without significant differences in the percentage of injured myocardium by triphenyltetrazolium chloride (TTC) staining and creatine kinase (CK) assay. Transmission electron microscopy analysis also confirmed necrosis with abundant mitochondrial damage in the IR hearts. All three IR groups exhibited significantly less mean (±standard error of the mean) tracer retention than matched controls (MIBI 73.4 ± 4.9% vs. 96.9 ± 1.76%, tetrofosmin 38.7 ± 4.6% vs. 82.2 ± 3.5%, and Q12 23.0 ± 2.5% vs. 43.8 ± 1.8%, respectively; P < 0.05). Tetrofosmin IR hearts exhibited 54 ± 9% of control myocardial retention, which was significantly less than either MIBI (86 ± 5%, P < 0.05) or Q12 (63 ± 6%, P < 0.05); thus, tetrofosmin provided the best differentiation between nonviable and normal myocardium. Furthermore, tetrofosmin end activity (%id/g) in controls was significantly higher than Q12 (4.09 ± 0.04 vs. 1.71 ± 0.06, respectively, P < 0.05), and tetrofosmin end activity (%id/g) in IR hearts was significantly higher than Q12 (2.19 ± 0.37 vs. 1.06 ± 0.12, respectively, P < 0.05). The correlation between end activity and viable myocardium determined by TTC staining was r = 0.66 (P < 0.05) for MIBI, r = 0.94 (P < 0.05) for tetrofosmin, and r = 0.91 (P < 0.05) for Q12. The correlation between myocardial end activity and myocardial CK leak was r = −0.62 (P < 0.05) for MIBI, r = −0.87 (P < 0.05) for tetrofosmin, and r = −0.89 (P < 0.05) for Q12.
Conclusions
Nonviable myocardium can be distinguished from normal myocardium by the retention kinetics of all three monocationic tracers studied. Tetrofosmin and Q12 end activities demonstrate the best correlation with infarct size. However, tetrofosmin kinetics may combine the greatest differentiation between nonviable and normal myocardium, while still retaining adequate activity for imaging.
Keywords
99mTechnetium Perfusion imaging agents Myocardial viability Ischemia ReperfusionPreview
Unable to display preview. Download preview PDF.
References
- 1.Dilsizian V, Roco TP, Freedman NM, Leon MB, Bonow RO. Enhanced detection of ischemic but viable myocardium by the reinjection of thallium after stress-redistribution imaging. N Engl J Med 1990;323:141–146.PubMedGoogle Scholar
- 2.Galassi AR, Ceutamore G, Fiscella A, Coppola A, Liberti F, Franco M, et al. Comparison of rest redistribution thallium-201 imaging and reinjection after stress redistribution for the assessment of myocardial viability in patients with left ventricular dysfunction secondary to coronary artery disease. Am J Cardiol 1995;75:436–442.PubMedCrossRefGoogle Scholar
- 3.McGoron AJ, Gerson MC, Biniakiewicz DS, Roszel NJ, Washburn LC, Millard RW. Extraction and retention of technetium-99m Q12, technetium-99m sestamibi, and thallium-201 in isolated rat heart during coronary acidemia. Eur J Nucl Med 1997;24:1479–1486.PubMedCrossRefGoogle Scholar
- 4.Bernard BF, Krenning EP, Breeman WA, Ensing G, Benjamins H, Bakker WH, et al. 99mTc-MIBI, 99mTc-tetrofosmin and 99mTc-Q12 in vitro and in vivo. Nucl Med Biol 1998;25:233–240.PubMedCrossRefGoogle Scholar
- 5.Rossetti C, Vanoli G, Paganelli G, Kwiatkowski M, Zito F, Colombo F, et al. Human biodistribution, dosimetry and clinical use of technetium (III)-99m-Q12. J Nucl Med 1994; 35:1571–1580.PubMedGoogle Scholar
- 6.Gerson MC, Millard RW, Roszell NJ, McGoron AJ, Gabel M, Washburn LC, et al. Kinetic properties of 99mTc-Q12 in Canine myocardium. Circulation 1994;89:1291–1300.PubMedGoogle Scholar
- 7.Galassi AR, Tamburino C, Grassi R. Comparison of technetium-99m tetrofosmin and thallium-201 single photon emission computed tomographic imaging for the assessment of viable myocardium in patients with left ventricular dysfunction. J Nucl Cardiol 1998;5:56–63.PubMedCrossRefGoogle Scholar
- 8.Okada RD, Nguyen KN, Lauinger M, Allton IL, Spreitzer K, Beju D, et al. Effects of no flow and reperfusion on technetium-99m-Q12 kinetics. J Nucl Med 1995;36:2103–2109.PubMedGoogle Scholar
- 9.Okada RD, Glover DK, Nguyen KN, Johnson G 3rd. Technetium-99m sestamibi kinetics in reperfused canine myocardium. Eur J Nucl Med 1995;22:600–607.PubMedCrossRefGoogle Scholar
- 10.Sinusas AJ, Shi QX, Saltzberg MT, Vitols P, Jain D, Wackers FJ, et al. Technetium-99m-tetrofosmin to assess myocardial blood flow: experimental validation in an intact canine model of ischemia. J Nucl Med 1994;35:664–671.PubMedGoogle Scholar
- 11.Kelley JD, Forster AM. Technetium-99m-tetrofosmin: a new radiopharmaceutical for myocardial perfusion imaging. J Nucl Med 1993;34:222–227.Google Scholar
- 12.Higley B, Smith FW, Smith T. Technetium-99m-1,2 bis (bis(20ethoxyethyl)phosphino)ethane:human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med 1993;34:30–38.PubMedGoogle Scholar
- 13.Arbab AS, Koizumi K, Toyama K, Arai T, Araki T. Technetium-99m-tetrofosmin, technetium-99m-MIBI and thallium-201 uptake in rat myocardial cells. J Nucl Med 1998;39:266–271.PubMedGoogle Scholar
- 14.Schaefer WM, Moka D, Brockmann HA, Schomaecker K, Schicha H. 201Tl, 99mMIBI, 99m tetrofosmin and 99m furifosmin: relative retention and clearance kinetics in retrogradely perfused guinea pig hearts. J Nucl Med Biol 2001;29:243–254.CrossRefGoogle Scholar
- 15.Glover DK, Ruiz M, Koplan BA, Watson DD, Beller GA. 99mTc-tetrofosmin assessment of myocardial perfusion and viability in canine models of coronary occlusion and reperfusion. J Nucl Med 1999;40:142–149.PubMedGoogle Scholar
- 16.Piwnica-Worms D, Kronauge JF, Chiu ML. Enhancement by tetraphenylborate of technetium-99m-MIBI uptake kinetics and accumulation in cultured chick myocardial cells. J Nucl Med 1991;32:1992–1999.PubMedGoogle Scholar
- 17.Nakamura K, Sammiya T, Hashimoto J, Ishibashi R, Matsumoto K, Kubo A. Comparison of cationic myocardial perfusion agents: characteristics of accumulation in cultured smooth muscle cells. Ann Nucl Med 1996;10:375–381.PubMedCrossRefGoogle Scholar
- 18.Arbab AS, Koizumi K, Toyama K, Araki T. Uptake of Tc-99m-tetrofosmin, Tc-99m-MIBI and Tl201 in tumor cell lines. J Nucl Med 1996;37:1551–1556.PubMedGoogle Scholar
- 19.Arbab As, Koizumi K, Toyama K, Araki T. Ion transport systems in the uptake of Tc-99m-tetrofosmin, Tc-99m-MIBI and Tl201 in a tumor cell line. Nucl Med Commun 1997;18:235–240.PubMedCrossRefGoogle Scholar
- 20.Piwnica-Worms D, Kronauge JF, Chiu ML. Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured chick myocardial cells: mitochondrial and plasma membrane potential dependence. Circulation 1990;82:1826–1838.PubMedGoogle Scholar
- 21.Carvalho PA, Chiu ML, Kronauge JF, Kawamura M, Jones AG, Holman BL, et al. Subcellular distribution and analysis of technetium-99m-MIBI in isolated perfused rat hearts. J Nucl Med 1992;33:1516–1521.PubMedGoogle Scholar
- 22.Meleca MJ, McGoron AJ, Gerson MC, Millard RW, Gabel M, Biniakiewicz D, et al. Flow versus uptake comparisons of thallium-201 with technetium-99m perfusion tracers in a canine model of myocardial ischemia. J Nucl Med 1997;38:1847–1856.PubMedGoogle Scholar
- 23.Liu Z, Okada DR, Johnson G, Hocherman SD, Beju D, Okada RD. 99mTc-sestamibi kinetics predict myocardial viability in a perfused rat heart model. Eur J Nucl Med Mol Imaging 2008;35:570–578.PubMedCrossRefGoogle Scholar